Navigation Links
Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
Date:11/5/2007

ed at least comparable efficacy and comparable safety vs. peginterferon alfa-2a (ITT analysis), with less impairment of quality of life on treatment and fewer lost days of work. The final Phase 2b results include the following SVR rates and other findings:

Albuferon 900-mcg Every Two Weeks (Albuferon 900 Q2w)

-- Based on an intention-to-treat (ITT) analysis, 58.5% of patients in the

Albuferon 900 Q2w treatment group achieved SVR, vs. 57.9% for

peginterferon alfa-2a administered every week.

-- In heavier patients (75 kg or heavier) who were treatment-adherent,

74.2% of those in the Albuferon 900 Q2w treatment group achieved SVR,

versus 53.3% for peginterferon alfa-2a.

-- Among all treatment-adherent patients in the Albuferon 900 Q2w

treatment group, 72.3% achieved SVR, versus 66.7% for peginterferon

alfa-2a.

-- Based on the SF-36 Health Survey, patients in the Albuferon 900 Q2w

treatment group reported less impairment of health-related quality of

life, compared with patients in the peginterferon alfa-2a treatment

group, as measured by both physical component and mental component SF-

36 summary measures at all time-points throughout the 48-week treatment

period.

-- Significantly fewer working patients in the Albuferon 900 Q2w treatment

group reported missing 7 days or more of work during the month prior to

their visits at Weeks 12 and 24, vs. the peginterferon alfa-2a group

(p<.05; Week 12: 4.2% for Albuferon 900 Q2w vs. 18.1% for

peginterferon alfa-2a; Week 24: 5.3% for Albuferon 900 Q2w, vs. 20.3%

for peginterferon alfa-2a).

-- The rate of discontinuations due to adverse events was 9.3% in the

Albuferon 900 Q2w treatment group, vs. 6.1% in the peginterferon alfa-

2a group. Adverse events observed were those typically expected with

interferon therapy. '/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... ... Meeting - A cumulative forty-five percent (45%) of patients ... medoxomil), and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) achieved ... mm Hg) (placebo:1.4%)., - Eight out of 10 (cumulative 81%) patients with ...
... La ... ... 14 /PRNewswire-,FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a,biopharmaceutical ... research organization, today announced,that an agreement has been executed licensing classes ...
Cached Medicine Technology:New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 2New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 3New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 4New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 5New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 7Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 3Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 4
(Date:7/9/2014)... 2014 There has been a sharp increase in ... Center using MyChart, the online, interactive service that allows ... their healthcare providers, schedule appointments, and renew prescriptions. , ... using MyChart each year increased five-fold, while ... than 10-fold, according to a study by Dr. ...
(Date:7/9/2014)... watching World Cup highlights, Brian Williams refreshing old school ... positions on railings. A University of Colorado Cancer Center ... shows that YouTube also allows researchers, journals, and health ... of skin cancer and prevention. , "No matter what ... how we communicate around the world," says Chante Karimkhani, ...
(Date:7/9/2014)... the most important organs in the human body. Its ... properly this is its synthesis function and ... this is its detoxification function. Lack of exercise and ... the liver. The resulting diseased cells can lead to ... failure. According to the German Liver Foundation, over five ...
(Date:7/9/2014)... kidney and heart disease have raised concerns about the ... in the first study to look closely at this ... the University of Pennsylvania report that older kidney donors ... cardiovascular health as very healthy older people who did ... increasing organ transplant waitlists, the authors of the study ...
(Date:7/9/2014)... diseases has risen dramatically in Western societies. One frequently ... microorganisms and have fewer infections than previous generations, thereby ... by researchers at Sahlgrenska Academy, University of Gothenburg, monitored ... of the immune system in relation to allergic disease. ... the Vstra Gtaland Region, half of them on farms ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2
... ... important questions to ask when choosing an alcohol rehab centre. , ... London, UK (PRWEB) June 17, 2009 -- Linwood Group announce that there ... in getting someone who is struggling with drink on the road to recovery. Having treatment in ...
... ... of leading cardiovascular disease centers in the United States exploring the efficacy of a ... treatment of patients with advanced congestive heart failure (CHF) who are on the waiting ... ...
... Health reform must deliver "evolutionary change" says new leader of ... J. James Rohack, M.D., a cardiologist from Bryan, Texas, was ... Association (AMA), the nation,s largest and most influential physician organization. ... ) , , In his inaugural address as ...
... , Independence Blue Cross and Philadelphia Business Journal to ... June 16 Americans spend more ... costs continuing to climb, many employers are looking for ways to ... In conjunction with Philadelphia Business Journal, Independence Blue Cross (IBC) is ...
... statin drugs, such as Lipitor (atorvastatin), does not lower the ... of more than 3,000 Group Health patients published online on ... ,s June 20 print issue. "Prior research based on ... statins as a way to prevent and treat infections including ...
... , Reporting System Provides Information to Improve Quality of , ... , WASHINGTON, June 16 URAC , ... CARF International , a premier, global, independent accreditor ... for case management professionals. The uSPEQ(R)/URAC Participant Experience ...
Cached Medicine News:Health News:Linwood Group Research Suggests 3 Questions Everyone Should Ask When Choosing an Alcoholic Residential Centre 2Health News:AGH Joins Select Group of Medical Centers in Study of Promising New Technology for Treatment of Heart Failure 2Health News:AGH Joins Select Group of Medical Centers in Study of Promising New Technology for Treatment of Heart Failure 3Health News:AGH Joins Select Group of Medical Centers in Study of Promising New Technology for Treatment of Heart Failure 4Health News:AMA Inaugurates J. James Rohack as President 2Health News:Employee Health and Reducing Health Care Costs Focus of Working Wellness Expo June 17 2Health News:Employee Health and Reducing Health Care Costs Focus of Working Wellness Expo June 17 3Health News:Statins don't lower risk of pneumonia in elderly 2Health News:URAC and CARF International Announce New Survey Tool for Health Care Case Management Studies 2Health News:URAC and CARF International Announce New Survey Tool for Health Care Case Management Studies 3Health News:URAC and CARF International Announce New Survey Tool for Health Care Case Management Studies 4
AccuSign® DOA Series Opiates Test...
... The SureStep™ Drug Screen Tests are ... assay for MDMA (Ecstasy). Designed using Microgenics ... is the only point of care immunoassay ... affinity for both MDA and MDEA but ...
The SEDITAINER Erythrocyte Sedimentation Rate (ESR) System is for collection of blood specimens for the measurement of ESR within the blood collection tube, using the SEDITAINER ESR Stand....
... NMP22® Test Kit is a quantitative microplate enzyme ... are at risk for rapid recurrence or occult ... voided urine sample and is twice as sensitive ... to improve patient outcome by identifying those patients ...
Medicine Products: